In addition, lysosomal activity of GC is tightly linked to expression of its trafficking receptor, the lysosomal integral membrane protein type-2 (LIMP-2), which acts as a chaperone helping to traffic glucosylceramidase from the endoplasmic reticulum to the lysosome; therefore, manipulating LIMP-2 expression to increase lysosomal GC activity is also a promising strategy for the treatment of synucleinopathies and GBA mutation carriers. This evidence concerns the gene SCARB2 and synucleinopathy.